Hematopoietic cell transplantation‐comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation

Elderly and medically infirm cancer patients are increasingly offered allogeneic nonmyeloablative hematopoietic cell transplantation (HCT). A better understanding of the impact of health status on HCT outcomes is warranted. Herein, a recently developed HCT‐specific comorbidity index (HCT‐CI) was compared with a widely acceptable measure of health status, the Karnofsky performance status (KPS).

[1]  M. Minden,et al.  Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  Sonali M. Smith,et al.  Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[3]  M. Sorror,et al.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. , 2005, Blood.

[4]  M. Sormani,et al.  Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation , 2005, Cancer.

[5]  T. Zimmerman,et al.  Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R Storb,et al.  Bone-marrow transplantation (second of two parts). , 1975, The New England journal of medicine.

[7]  G. Morgan,et al.  In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. , 2000, Blood.

[8]  M. Brechbiel,et al.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. , 2002, Blood.

[9]  M. Sorror,et al.  Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Glomstein,et al.  [Bone marrow transplantation. A review]. , 1981, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[11]  R. Brand,et al.  Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning , 2003, Leukemia.

[12]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[13]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[14]  C. Flowers,et al.  Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.

[15]  Q. Springer-Verlag.  Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996 , 1999 .

[16]  T. Irimura,et al.  Lack of antigen-specific tissue remodeling in mice deficient in the macrophage galactose-type calcium-type lectin 1/CD301a. , 2005, Blood.

[17]  H. Gundacker,et al.  Age and acute myeloid leukemia. , 2006, Blood.

[18]  K Bandeen-Roche,et al.  Association of comorbidity with disability in older women: the Women's Health and Aging Study. , 1999, Journal of clinical epidemiology.

[19]  J. Radich,et al.  Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.

[20]  H. Deeg,et al.  Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  A. Dyer,et al.  Body Mass Index, Abnormal Glucose Metabolism, and Mortality from Hematopoietic Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.

[22]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[23]  J. Fleiss.  The design and analysis of clinical experiments , 1987 .

[24]  C. Flowers,et al.  Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.

[25]  R. Storb,et al.  Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission , 2007, Current opinion in hematology.

[26]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[27]  M. de Lima,et al.  Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. , 2006, Seminars in hematology.

[28]  C. Solano,et al.  Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trial , 2004, Bone Marrow Transplantation.

[29]  R. Storb,et al.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. , 2003, Blood.

[30]  D. Blaise,et al.  Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[32]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[33]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[34]  Anajane G. Smith,et al.  Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. , 1998, Blood.

[35]  Hisayuki Yokoyama,et al.  Increased expression of insulin-like growth factor i is associated with Ara-C resistance in leukemia. , 2006, The Tohoku journal of experimental medicine.

[36]  H. Kantarjian,et al.  The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. , 2007, British journal of haematology.

[37]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[38]  J. Samet,et al.  A population-based study of functional status and social support networks of elderly patients newly diagnosed with cancer. , 1991, Archives of internal medicine.

[39]  E. Gore,et al.  Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. , 2002, International journal of radiation oncology, biology, physics.

[40]  O. Nanni,et al.  Haematopoietic cancer and medical history: a multicentre case control study , 2000, Journal of epidemiology and community health.

[41]  Joseph L. Fleiss,et al.  The Design and Analysis of Clinical Experiments: Fleiss/The Design , 1999 .

[42]  H. Deeg,et al.  Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis , 2006, Leukemia.

[43]  H. Deeg,et al.  Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  D. Karnofsky.  The clinical evaluation of chemotherapeutic agents in cancer , 1949 .

[45]  M. Munsell,et al.  Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[46]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[47]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[48]  M. Extermann,et al.  Interaction between comorbidity and cancer. , 2007, Cancer control : journal of the Moffitt Cancer Center.

[49]  W. Siegert,et al.  Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor , 2003, Bone Marrow Transplantation.

[50]  M. Boeckh,et al.  Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients. , 1999, Blood.

[51]  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000 .

[52]  L. Balducci,et al.  The application of the principles of geriatrics to the management of the older person with cancer. , 2000, Critical reviews in oncology/hematology.

[53]  J. Armitage,et al.  Allogeneic bone marrow transplantation for low-grade lymphoma. , 1998, Blood.

[54]  M. Boeckh,et al.  Infection in Hematopoietic Stem Cell Transplantation , 2002 .

[55]  S. Crawford,et al.  Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Rubin,et al.  Clinical Approach to Infection in the Compromised Host , 2002, Springer US.

[57]  J. Delgado,et al.  Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. , 2006, Blood.

[58]  P. Mclaughlin,et al.  Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. , 2001, Blood.

[59]  M. Sorror,et al.  Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  G. Lyman,et al.  Comorbidity and functional status are independent in older cancer patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  A. Nagler,et al.  Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity , 2006, Leukemia.

[62]  X. Thomas,et al.  Cigarette Smoking and Acute Leukemia , 2004, Leukemia & lymphoma.

[63]  A. Nagler,et al.  Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.

[64]  R. Day,et al.  The oncogenicity of chlorambucil in rheumatoid arthritis. , 1988, British journal of rheumatology.

[65]  P. Valagussa,et al.  Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Y. Kwong,et al.  Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: association with -7/7q-. , 1998, Cancer genetics and cytogenetics.

[67]  E. Estey,et al.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.

[68]  P. Thall,et al.  Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[69]  J. Gribben,et al.  Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.

[70]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[71]  J. Coebergh,et al.  Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996 , 1999, Annals of Hematology.

[72]  G. Mufti,et al.  Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. , 2006, Blood.

[73]  R Storb,et al.  Bone-marrow transplantation (first of two parts). , 1975, The New England journal of medicine.

[74]  S. Heimfeld,et al.  HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. , 2003, Blood.

[75]  X. Thomas,et al.  Influence of cigarette smoking on the presentation and course of acute myeloid leukemia. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  M. Maris,et al.  Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases. , 2005 .

[77]  M. Sorror,et al.  Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. , 2007, Blood.

[78]  M. Maris,et al.  Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. , 2007, Blood.

[79]  S. Mineishi,et al.  Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.

[80]  G. Mufti,et al.  Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.